<unk>  is a phenothiazine derivative with Vaughan Williams class IC antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34-38 percent, and is 95 percent bound to plasma proteins.<unk>  is extensively metabolized and may have pharmacologically active metabolites. A recent clinical study has shown that<unk>  is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine,<unk>  was equally or more effective in suppressing ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia. Further studies are needed comparing<unk>  with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that<unk>  is comparable with these agents in the treatment of ventricular tachycardias and fibrillation.<unk>  appears to have a low incidence of serious adverse effects compared with other antiarrhythmics. This combination of apparently similar efficacy with a decreased incidence of adverse effects makes<unk>  a worthwhile addition to currently available antiarrhythmic agents.
Moricizine
Prodine
Moracizine
Ethacizine
Niperotidine
Hexetidine
Famotidine 
Bromopride